Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.42 |
| ▸ | SQLE | Q14534 | 6/20 | 0.41 |
| ▸ | LSS | P48449 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1270897 | 1.00 | KMT2A (0.46) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL21954156 | 0.91 | TSHR (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL2108765 | 0.91 | TSHR (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| SCHEMBL111818 | 0.91 | TSHR (0.48) | KMT2AALOX15MEN1CYP3A4ALDH1A1 | |
| Myrcene SCHEMBL6465671 | 0.88 | TSHR (0.65) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL19177673 | 0.83 | TSHR (0.42) | ALDH1A1TSHR | |
| SCHEMBL9956466 | 0.83 | LSS (0.53) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL9955815 | 0.83 | LSS (0.53) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL9954138 | 0.83 | LSS (0.53) | KMT2AALOX15MAPTMEN1CYP3A4 | |
| SCHEMBL9954133 | 0.83 | LSS (0.53) | KMT2AALOX15MAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140148623-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-8450549-B2 | Fuel compositions comprising isoprene derivatives | DANISCO US INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-2448891-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | Danisco US Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| US-20110046422-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. | 2011-02-24 | — | — | US | disclosed |
| WO-2010148256-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | DANISCO US INC. (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046422-A1 | FUEL COMPOSITIONS COMPRISING ISOPRENE DERIVATIVES | GGPS1, FNTA, COASY | KMT2A 4126/4885ALOX15 244/4885MAPT 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.